Clinical Trial Update: A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 neoadjuvant trial comparing ARX788 plus pyrotinib to trastuzumab plus pertuzumab with docetaxel and carboplatin in HER2-positive breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARX788
• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Caigang Liu | Conditions: HER2-positive Breast Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING